Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14020589 | 0.83 | TRPA1 (0.48) | AMY1ANPSR1TRPA1MAPTHPGD | |
| SCHEMBL29621432 | 0.82 | AMY1A (0.83) | AMY1ANPSR1TRPA1MAPTMEN1 | |
| SCHEMBL29402131 | 0.82 | AMY1A (0.83) | AMY1ANPSR1TRPA1MAPTMEN1 | |
| SCHEMBL50622 | 0.82 | AMY1A (0.83) | AMY1ANPSR1TRPA1MAPTMEN1 | |
| SCHEMBL2795115 | 0.82 | NPSR1 (0.55) | AMY1ANPSR1PKMTRPA1MAPT | |
| SCHEMBL11674343 | 0.81 | EGFR (0.60) | PKMMAPTHPGDRECQLTDP1 | |
| SCHEMBL23997632 | 0.80 | KDM4E (0.47) | AMY1AHSD17B10ALDH1A1KDM4E | |
| Methyl Alcohol SCHEMBL3081581 | 0.80 | AMY1A (0.80) | AMY1ANPSR1TRPA1MAPTMEN1 | |
| SCHEMBL12809240 | 0.80 | HTR2A (0.47) | GAALMNA | |
| SCHEMBL15383498 | 0.80 | AMY1A (0.52) | AMY1ANPSR1PKMTRPA1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113437341-B | Amphoteric ion conduction membrane for flow battery and preparation method thereof | 泰山学院 | 2022-04-12 | — | — | CN | claimed |
| CN-113437341-A | Amphoteric ion conduction membrane for flow battery and preparation method thereof | 泰山学院 | 2021-09-24 | — | — | CN | claimed |
| US-20230181494-A1 | COMPOSITIONS AND METHODS OF USE OF GAMMA-KETOALDEHYDE SCAVENGERS FOR TREATING, PREVENTING OR IMPROVING NONALCOHOLIC FATTY LIVER DISEASE (NAFLD), NASH, ALD OR CONDITIONS RELATED TO THE LIVER | MTI BIOTECH, INC. | 2023-06-15 | — | — | US | disclosed |
| CN-113437341-B | Amphoteric ion conduction membrane for flow battery and preparation method thereof | 泰山学院 | 2022-04-12 | — | — | CN | disclosed |
| CN-113437341-A | Amphoteric ion conduction membrane for flow battery and preparation method thereof | 泰山学院 | 2021-09-24 | — | — | CN | disclosed |
| US-10188627-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | MITOBRIDGE, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-10188627-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | MITOBRIDGE, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170304255-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2017-10-26 | — | — | US | disclosed |
| US-20170304255-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2017-10-26 | — | — | US | disclosed |
| US-20170304255-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2017-10-26 | — | — | US | disclosed |
| WO-2016057660-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MITOBRIDGE, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20100278933-A1 | KINASE INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC (US) | 2010-11-04 | — | — | US | disclosed |
| US-20080262031-A1 | 4-Aminoquinoline Derivatives as Antimalarials | CTG PHARMA S.R.L. (IT) | 2008-10-23 | — | — | US | disclosed |
| US-20080262031-A1 | 4-Aminoquinoline Derivatives as Antimalarials | CTG PHARMA S.R.L. (IT) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278933-A1 | KINASE INHIBITOR COMPOUNDS | MAP3K1, MAP3K2, MAP3K6 | AMY1A 4682/4885NPSR1 3788/4885PKM 487/4885 |
| US-10188627-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | PPARG, PPARD, PPARA | AMY1A 2903/4885NPSR1 2449/4885PKM 387/4885 |
| US-20230181494-A1 | COMPOSITIONS AND METHODS OF USE OF GAMMA-KETOALDEHYDE SCAVENGERS FOR TREATING, PREVENTING OR IMPROVING NONALCOHOLIC FATTY LIVER DISEASE (NAFLD), NASH, ALD OR CONDITIONS RELATED TO THE LIVER | CPT1A, AKR7A2, FABP1 | AMY1A 306/4885NPSR1 3020/4885PKM 125/4885 |
| US-20080262031-A1 | 4-Aminoquinoline Derivatives as Antimalarials | QTRT1, QTRT2, RECQL | AMY1A 4434/4885NPSR1 3865/4885PKM 435/4885 |
| US-20170304255-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARD, PPARA | AMY1A 2903/4885NPSR1 2449/4885PKM 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.